Corpus ID: 25201025

A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.

@article{Ili1998ARP,
  title={A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.},
  author={Fikri Içli and Ismail Çelik and Faruk Aykan and Aytug Uner and Ahmet Demirkazık and Ahmet Ozet and Mustafa Ozg{\"u}roğlu and Faruk Tas and Hakan Akbulut and Di̇nçer Firat},
  journal={Cancer},
  year={1998},
  volume={83 12},
  pages={
          2475-80
        }
}
BACKGROUND Gastric carcinoma is a substantial health problem in Turkey, and the majority of patients present with inoperable disease. The aim of this randomized trial was to assess the activity of 5-fluorouracil versus etoposide when combined with epirubicin plus cisplatin in patients with advanced gastric carcinoma (AGC). METHODS In this prospective, randomized, multicenter Phase III study, previously untreated patients with histopathologically proven AGC enrolled after giving informed… Expand
Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in unresectable or metastatic gastric cancer: A single institution experience
TLDR
It is confirmed that this regimen is very active and well tolerated in unresectable or metastatic gastric cancers and in conclusion, its use in previously untreated patients is confirmed. Expand
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
TLDR
The phase I/II trial showed S-1 combined with CPT-11 is effective for AGC and is well tolerated, with acceptable toxicity. Expand
Docetaxel in gastric cancer
TLDR
At a planned interim analysis on 223 patients, both the median time to progression and overall response rate were statistically superior in the DCF arm, and the increase in median survival in this interim analysis did not yet reach statistical significance. Expand
Advanced gastric cancer--slow but steady progress.
TLDR
With the addition of targeted therapy, especially anti-angiogenic and anti-Her2 therapy, and a better understanding of the biology of the disease, perhaps a sense of optimism should indeed suppress the nihilism commonly associated with this disease. Expand
Targeted therapy for gastric cancer—current status
TLDR
In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to chemotherapy significantly improved overall survival compared with chemotherapy alone and did not increase the incidence of adverse events. Expand
Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995–2001
TLDR
New agents are being widely incorporated in the investigation of advanced gastric cancer in North America and Europe, and this trend is likely to be continued as more new chemotherapeutic agents are developed for clinical testing. Expand
Timing of Death From Tumor Recurrence After Curative Gastrectomy for Gastric Cancer
TLDR
Lymph node status was the most important factor predictive for early versus late recurrence and patients with lymph node metastases were at more risk of death within 2 years after curative operation for gastric cancer. Expand
Epirubicin, Cisplatin, and Fluorouracil (ECF) Regimen
TLDR
This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases. Expand
Nuevas alternativas en el tratamiento del cancer gástrico avanzado
Patients with stage IV gastric cancer, according to the American JointCommittee on Cancer or with relapsed disease and functional capacity 0-2 of the South WestOncology Group, were included. FOLFOX-4Expand